Report date: Wednesday, August 5, 2026, after market close Call: 2026Q2 Earnings Call
Solventum heads into this print red-hot. Shares have run from the low-$60s in March to a 52-week high near $88 in the days before earnings, fueled by a strong Q1 beat, multiple sell-side rating upgrades (UBS to Buy/$95 PT, Wedbush initiating Outperform at $94, BTIG raising to $91, Stifel to $90), and — perhaps most notably — disclosure that activist investor Nelson Peltz's Trian Fund Management has built a meaningful stake, pushing for faster portfolio separation (including a possible split of dental and software assets). Wedbush initiated coverage on Solventum with an Outperform rating and a $94.00 price target, highlighting the stock as a compelling special situation, noting the company has faced challenges as a standalone entity with adjusted EBIT compressing roughly 480 basis points from pre-spin levels. Options activity has also spiked heading into the print, signaling the market expects a large move.
That run-up raises the bar: expectations are elevated, and any stumble — particularly around the messy revenue-phasing dynamics management flagged last quarter — could trigger a sharp reaction either way.
Solventum is scheduled to release second-quarter 2026 results on Aug. 5, after market close, with the Zacks Consensus Estimate for revenues pegged at $2.17 billion and the consensus mark for earnings at $1.91 per share. Analysts expect SOLV to report a profit of $1.91 per share, up 13% from $1.69 per share in the year-ago quarter. The company has beaten consensus estimates in each of the past four quarters. For the full year, analysts expect SOLV to report EPS of $6.58, up 7.7% from $6.11 in fiscal 2025.
Despite the recent rally, Solventum has lagged the S&P 500's 19.1% gain and the Health Care Select Sector SPDR's 22.2% return over the past 52 weeks, with shares up only 8.7% during that period, amid investor concerns about weak growth and profitability, as the company has reported little to no organic revenue growth while analysts expect roughly flat sales over the next 12 months. That's the tension for this print: sentiment has clearly turned more constructive (Trian stake, rating upgrades), but the underlying growth algorithm remains modest.
On the Q1 call, management pre-announced a significant complication for Q2 results. As part of mitigating the U.S./Canada ERP cutover from 3M's legacy systems planned for Q3 2026 — the largest and most complex of the remaining separation cutovers — Solventum pulled forward customer orders through distributors, primarily benefiting Infection Prevention & Surgical Solutions (IP&SS) and Dental. CFO Wayde McMillan estimated this would add "over $100 million of sales timing benefit in Q2 that we expect will reverse in 2026, mostly in Q3."
Management explicitly told investors not to adjust full-year models and to expect this pull-forward to mechanically flow through: roughly 5% incremental sales with ~30% drop-through to EPS, reversing mostly in Q3. Reported revenues in Q2 are expected to have benefited from more than $100 million of advanced customer orders ahead of the planned U.S. ERP cutover.
What to watch on the call: - The actual magnitude of the pull-forward (management guided ~$100M but said it could be "higher or lower") - Underlying/normalized organic growth once that benefit is stripped out — this is the real read on business momentum - Any early commentary on Q3 given the ERP cutover is now imminent, since a botched cutover is a real execution risk with a large, mostly distribution-based U.S. business
Solventum's second-quarter performance is expected to reflect continued strength in commercial execution across the MedSurg, Dental and Health Information Systems segments, with contributions from the Acera acquisition and ongoing cost-saving initiatives also likely to support results.
Q1 delivered 80bps of adjusted gross margin expansion (56.4%) despite tariff and inflation headwinds, aided by portfolio moves (P&F divestiture, Acera) and Transform for the Future savings. Management guided gross margin to step down slightly for the rest of the year (just under 56%). Key threads to track: - Full-year adjusted operating margin guidance of 21.0%–21.5% (+50–100bps y/y) despite an annualizing $100M–$120M tariff headwind - Progress on the $500M multiyear "Transform for the Future" savings program (benefits weighted more to 2027+) - Any commentary on potential tariff refunds (none currently booked in results)
As of Q1, Solventum had exited just over 50% of Transition Service Agreements (on pace for >90% by year-end) and migrated 75% of 1,200+ legacy systems, including a completed Asia-Pacific/China ERP cutover. The U.S./Canada ERP cutover in Q3 2026 is the last major one — management expressed high confidence in mitigation plans (leveraging the fact that most U.S. sales flow through distributors), but this remains the single largest operational risk on the calendar for the next quarter.
Management has been explicit that portfolio reshaping is a "perpetual lever," pointing to the P&F divestiture (~$4B, described by CEO Bryan Hanson as one of the best multiples in the sector) and the Acera acquisition as proof points, while declining to rule out further divestitures or acquisitions. This dovetails with reports that Trian has taken a large stake and is advocating for more aggressive action than management's current pace, including separating dental products and software operations, believing the company is moving too slowly on its transformation. Expect analysts to press management on portfolio strategy and capital deployment on the call, especially given the stock's recent re-rating.
Upside catalysts: - Clean beat on both revenue and EPS with underlying (ex-pull-forward) organic growth trending toward or above the 4-5% LRP target - Reaffirmed or raised full-year EPS guidance (already signaled toward the high end of $6.40–$6.60) - Positive read-through on Acera integration and new product cadence (~20 launches over two years) - Any incremental color on portfolio actions given Trian involvement
Downside risks: - Confusion or disappointment around the ERP-driven revenue phasing making the quarter hard to interpret - Signs of risk to the Q3 U.S. ERP cutover given its scale and complexity - Tariff cost escalation beyond the $100M–$120M guided range - Given the stock's sharp run into the print, even an in-line quarter with unchanged guidance could trigger profit-taking after a ~25%+ rally off spring lows
Solventum goes into its Q2 print with real operational momentum (Q1 beat, margin expansion, faster-than-expected separation progress) and a much friendlier investor narrative (activist involvement, rating upgrades) than it had just a few months ago. But the quarter itself is complicated by design — a >$100M order pull-forward tied to the year's biggest remaining ERP cutover means headline revenue and EPS should look strong, while the real test is whether management can convincingly show underlying growth is still tracking toward its 4-5% long-range target, and whether the U.S. ERP transition in Q3 goes as smoothly as promised. With the stock near 52-week highs and consensus already expecting a 13% EPS beat, the bar for a positive reaction is higher than the raw guidance-beat/raise history would suggest.